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Classifying disease activity in asthma relies on clinical and physiological variables, but these
variables do not capture all aspects of asthma that distinguish levels of disease activity.
We used data from two pivotal trials of montelukast in asthma to classify disease activity as
“high” or “low.” We performed a principal component analysis (PCA) of disease activity using
21 efficacy outcome variables, including several novel derived outcome variables reflecting
clinical and airway obstruction lability. Then we performed discriminant analysis (DA) based
on disease activity classification.
PCA revealed 6 factors (daytime asthma control, nighttime-predominant asthma control,
airway obstruction, exacerbations, clinical lability, airway obstruction lability) that explained
76% of the variance between outcome variables. Although airway obstruction lability
(comprising both diurnal variability in peak expiratory flow and diurnal variability in b-agonist
use) accounted for only 6% of the explained variance in PCA, in DA it was more accurate
(canonical coefficient 0.75) than traditional measures of asthma severity such as obstruction
(0.54) and daytime control (0.56) in distinguishing between high and low disease activity.
We conclude that airway obstruction lability, a parameter not typically captured in clinical
trials, may contribute to more complete assessment of asthma disease activity and may define
an emerging clinical target of future therapy.
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asthma disease activity in the study population.Randomized clinical trials in asthma typically use well-
defined efficacy outcome measures, such as forced expi-
ratory volume in 1 s (FEV1) and rescue b-agonist use. The
chief benefits of such outcome measures are their repro-
ducibility and widespread use, but it is also recognized that
asthma outcome measures correlate poorly with one
another.1 It is not always clear that improvement in a given
outcome measure, such as FEV1, is truly indicative of clin-
ical improvement that is perceived broadly, including by
patients and clinicians.1,2
For a patient to show evidence of clinical improvement,
the patient’s clinical status must approach that of a patient
with a lower level of disease activity. Therefore, a neces-
sary first step in defining response to asthma therapy is to
distinguish different levels of disease activity. Over the past
two decades, several approaches to defining different
levels of disease severity or activity have been proposed,
including the Global Initiative for Asthma (GINA) guidelines3
and the National Heart Lung and Blood Institute’s (NHLBI)
Expert Panel Report 3 (EPR3).2 The most recent effort at
defining asthma disease severity is based on “the lowest
level of treatment required to achieve patient’s best level
of asthma control”.4 While this intuitive approach has many
advantages, it is often difficult to define a patient’s best
level of control; patients can be over-treated, potentially
overestimating the patient’s disease burden. Furthermore,
it may be difficult to compare one patient’s best level of
control with that of another’s. This poses difficulties in
applying such a definition of asthma severity in a clinical
trial setting, where between-group comparisons are
important. Perhaps the greatest challenge to the use of
such an outcome measure is that clinical study designs
typically include a run-in period in which a patient’s
controller regimen is typically titrated down or off, or
switched to a study-approved background therapy, which
may not necessarily be at a dose equivalent to that of
prestudy therapy. Changing the dosage of these controllers
as part of the clinical trial design complicates this approach
to defining disease severity. Therefore, an asthma
responder index has important implications not only in
clinical settings, but also in supporting development of
novel therapeutics for asthma; it is often difficult to
determine how best to use clinically important outcome
measures to define a robust clinical response to therapy.5
An initial step in defining the clinical characteristics of
a “responder” to an asthma therapy requires an under-
standing of the clinical features that distinguish between
asthmatics on the spectrum of disease severity. Therefore,
the objective of this study is to determine which among
many efficacy outcome variables best distinguishes patients
with high and low burdens of disease. Our hypothesis is that
among commonly used clinical outcome variables, some
will better distinguish asthmatics with high and low disease
activity. Using the montelukast pivotal trials6,7 as a test
dataset, we performed a principal component analysis
(PCA), which groups outcome variables that are similar and
establishes which grouping of variables best explains the
variance in the data. We then applied discriminant analysis
(DA) to the output of the PCA to identify which groupings ofvariables best distinguished between high and low levels ofMethods
Clinical trial database
Full reports of the three large Phase-III clinical trials used in
this analysis have been published previously.6e8 From the
first two trials,6,7 a combined dataset was used to generate
a factor structure through PCA, followed by discriminant
analysis. The third trial8 was used to confirm the results of
the first two trials. Briefly, each of the first two trials
consisted of a 2-week, single-blind placebo run-in period,
a 12-week, double-blind active treatment period, and a 3-
week, double-blind placebo washout period. In both
studies, healthy, nonsmoking men and women 15 years of
age with at least a 1-year history of asthma who met pre-
specified criteria regarding lung function, reversibility, and
asthma symptoms were eligible; qualifying patients were
randomized to receive montelukast (both studies), beclo-
methasone (one study6), or placebo (both studies) during
the active treatment periods. In the confirmatory trial,
healthy, nonsmoking, male and female patients (15 years
of age), with a history of at least one year of intermittent or
persistent asthma symptoms treated with inhaled cortico-
steroids for at least 6 weeks were recruited for the study.
The study was a double-blind, double-dummy, randomized
controlled parallel-group trial whose objective was to
determine whether montelukast provides additional clin-
ical benefit to the effect of inhaled corticosteroids.8
Efficacy outcome variables
In all studies, morning FEV1 was measured at each visit
during the baseline and active treatment periods. For the
combined dataset, asthma-specific quality-of-life (AQLQ)
was assessed at baseline (Week 0), Week 3, and Week 12.
For the confirmatory trial, AQLQ was measured at Week 4,
upon reduction of inhaled corticosteroids, and at Weeks 8
and 20. In all studies, rescue b-agonist use, daytime
symptom score, and peak expiratory flow (PEF; morning
and evening) were derived from patient entries on the daily
diary card during the baseline and active treatment
periods. Daytime symptom score (DSS; 0 to 6 scale) was
based on 4 questions, two that reflected asthma symptoms:
“How often did you experience asthma symptoms today?”;
“How much did your asthma symptoms bother you today?”;
and two that reflected activity level: “How much activity
could you do today?”; “How often did your asthma affect
your activities today?” An asthma exacerbation was defined
by any one of the following criteria: decrease in AM PEF of
>20% from baseline, AM PEF <180 L/min, an increase from
baseline in b-agonist use of >70% (and a minimum increase
of 2 puffs), an increase of >50% from baseline in daytime
symptom score, awake “all night” on the overnight diary, or
the occurrence of an asthma attack. An “asthma attack”
was defined as an unscheduled asthma care visit in an
office, emergency room, or hospital setting, or oral corti-
costeroid rescue for worsening asthma. A “corticosteroid
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venous, or intramuscular) to relieve an asthma attack. An
“asthma-free day” was defined as any one day when all of
the following criteria were met: no asthma attacks, no
rescue medication (corticosteroids, cromolyn [oral, inhaled,
nebulized], epinephrine, nebulized salbutamol, bronchodi-
lators other than inhaled salbutamol), no nocturnal awak-
enings, and use of 2 puffs of b-agonist. Asthma attacks,
asthma exacerbations, asthma-free days, and oral cortico-
steroid rescues (all derived from patient entries on the daily
diary card during the treatment period) were on-treatment
measures and therefore did not have baseline values.
Because studies have indicated that diurnal variability in
PEF tends to correlate with the severity of asthma symp-
toms,9 we included this variable in our analysis. Similarly,
we also included variables that reflected diurnal variability
in rescue b-agonist use as well as day-to-day variation in
asthma symptoms: (1) Diurnal variability of PEF, average
over three weeks of daily determinations:
jAM PM PEFj=Average of AM and PM PEF; (2) Diurnal
variability of rescue b-agonist use, average over three
weeks of daily determinations: jAM PM rescue
b agonist use j=Average of AM and PM rescue b agonist
use; and (3) Between-day variability in daytime asthma
symptom score, average over three weeks of daily deter-
minations: jDSS at day t DSS at dayðt 1Þj=Average of
DSS at day t and dayðt 1Þ. Other endpoints were collected
as previously described.6,7Defining disease activity
Analogous to the rheumatoid arthritis disease activity
score,10 we defined asthma disease activity based on
patients’ manifestations of asthma regardless of the level
of treatment intensity. We specifically avoided the terms of
asthma disease “severity” or “control” to avoid conflating
our definitions with these related parameters. Inclusion
criteria precluded patients with a low level of disease
activity from entering the trials. Therefore, to better
represent a wider spectrum of asthma activity, we defined
levels of disease activity not at baseline, but instead based
on the efficacy outcome data from the combined dataset at
Week 12. This approach thereby included patients who
achieved significant improvement from treatment drug and
had attained a low level of disease activity.
We established rules for classifying disease activity as
“high” or “low” (Table 1) using clinical and statistical
criteria; cutoffs for disease activity were based principally
on guidelines established by GINA3 and by the EPR3.2 To be
designated as having “high” disease activity, patients had
to meet at least one of the high disease activity criteria at
Week 12; defining high disease activity according to the
most severe attributes recognizes the clinical heteroge-
neity of asthma and is generally in accord with GINA and
EPR3 guidelines. To be designated as having “low disease
activity,” patients had to meet all of the low disease
activity criteria at Week 12, which helped ensure that low
disease activity was truly low and also is generally in accord
with GINA and EPR3 guidelines. By default, patients who
were in neither the high nor low disease activity categories
were classified as having “moderate” disease activity. Toavoid redundancy in the criteria, we limited the DSS to the
“symptom” component (rather than the symptom and
activity components) and the AQLQ to the activity domain,
rather than any combination of all domains, including the
symptom domain. Cutoffs conformed to the scales of the
outcome variables in the dataset.
Statistical approach
After identifying 21 efficacy outcome variables, we per-
formed PCA, a type of multivariate analysis related to factor
analysis that reveals the internal structure of the data that
best explains the variance in the data. PCA is useful in cases
when there is a high likelihood of redundancy in a large set
of variables; in this context, redundancy means that some of
the variables are correlated with one another, possibly
because they are measuring the same construct. Because of
this redundancy, it may be possible to reduce the observed
variables into a smaller number of principal components
that account for most of the variance in the observed vari-
ables. The principal components can be used as predictor or
criterion variables in subsequent analyses, such as discrim-
inant analysis. One of the strengths of PCA is that it is a non-
parametric method used to simplify the information
provided by complex datasets. However, this can be viewed
as a weakness, as prior knowledge of the system being
analyzed cannot be incorporated into the algorithm.11
Principal component analysis was followed by discriminant
analysis to derive the discriminant function, a continuous
dependent variable and to determine which factors best
distinguish between levels of disease severity. Six factors
were used in the discriminant analysis of groups of patients
with low and high disease activity.
As we have employed several variables in defining
disease activity for which there are no specific proposed
cutoffs to distinguish levels of asthma severity (i.e., DSS
and AQLQ), we performed a sensitivity analysis by varying
the cutoffs in these variables and then re-defining the
levels of disease activity as a function of these revised
cutoffs; the varied cutoffs were defined based on the SD of
the respective variables.
All data were analyzed using SAS Version 9.1 (Cary, NC).
Results
Patient population
Baseline characteristics of the combined dataset were
previously presented in study-specific publications.6,7 In
the combined dataset, 1114 patients had available Week 12
data and were included in the present analysis. Median age
(range) was 34.5 (15e79) years (Table 2). Fifty six percent
were female, and 73% had a history of allergic rhinitis. Most
patients would be classified as having moderate or severe
persistent asthma by GINA criteria.
Principal component analysis
Using the 21 efficacy outcome variables (which are listed in
Table 3), the PCA produced groupings of efficacy variables,
Table 1 Cutoffs and rationale for cutoffs used to define high and low levels of disease activity for combined dataset.
High disease
activity
Low disease
activity
Rationale for indicated cutoffs
Any of below All of below
Average DSS, symptom
component
3.2 1.6 High: mean þ 1 SD DSS of patients that
otherwise fit criteria
Low: mean  1 SD DSS of patients that
otherwise fit criteria
Nocturnal awakenings (NA) 4/week 1/week High: corresponds to NA previously noted
in “very poorly controlled” asthmatics2
Low: corresponds to NA previously noted
in “mild” asthmatics (3e4/month)2
Average rescue
b-agonist use
4 puffs/day 1 puff/day High: rescue b-agonist use previously
noted in “very poorly controlled” or
“severe disease”2; likely to use rescue
b-agonist on at least 2 occasions/day
Low: rescue b-agonist use previously
noted in “mild disease:” not daily
or >1/day; 1 puff/day2 f lowest
level of rescue b-agonist use2
AQLQ-activity domain 2.9 5.0 High: mean  1 SD AQLQ-activity domain
in patients whose ATAQ is 3 or 426;
corresponds to “Very limited” in activity
Low: average of mean  1 SD AQLQ-activity
domain in patients whose ATAQ score is 027;
corresponds to “Some limitation” in activity2
FEV1 (% predicted) <60% 80% High: corresponds to % predicted FEV1
previously noted in “very poorly
controlled” or “severe” asthmatics2
Low: corresponds to % predicted FEV1
previously noted in “well controlled” or
“mild” asthmatics2
Asthma attacks 1 or more None Unscheduled asthma care in an office,
ER, or hospital setting, or initiation of
oral corticosteroids to relieve an
asthma attack.
ATAQ Z asthma therapy assessment questionnaire, AQLQ Z asthma quality-of-life questionnaire, DSS Z daytime symptoms score,
FEV1 Z forced expiratory volume in 1 s; SD Z standard deviation.
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eigenvalues 1.0 (Fig. 1) and cumulatively explained 76% of
the variance in disease activity, as measured across the 21
efficacy outcome variables. The 6 factors and correspond-
ing magnitude of explained variance, respectively, were:
daytime asthma control (33%); nighttime-predominant
asthma control (13%); airway obstruction (9%); exacerba-
tions (8%); clinical lability (7%); and airway obstruction
lability (6%) (Table 3).Discriminant analysis
We used the 6 factors identified above in the DA, which
revealed an overall canonical correlation (i.e., discrimi-
nating power) of 0.69 and a correct disease activity clas-
sification rate of 98.3% (Table 4).
Factors that were significantly correlated with the
discriminant function were daytime asthma control,
nighttime-predominant asthma control, airway obstruction,exacerbations, clinical lability, and airway obstruction
lability. Of interest, despite accounting for only 6% of the
explained variance among the 21 outcome variables in the
PCA (Table 3), airway obstruction lability, comprising both
PEF diurnal variability and rescue b-agonist diurnal vari-
ability, better discriminated patients with high and low
levels of disease activity (i.e., with a higher correlation,
0.75, in Table 4) than did the more traditional asthma
endpoints of airway obstruction (e.g., FEV1), exacerbations,
and daytime asthma control (e.g., daytime symptom score).
The only factor with greater discriminant power was
nighttime-predominant asthma control.Sensitivity and subgroup analyses
To determine whether the specific cutoffs we chose
affected the overall findings of this study, we performed
a sensitivity analysis focused on cutoffs for those variables
that were not as clearly defined in the literature as being
Table 2 Patients’ baseline characteristics in combined dataset (N Z 1114).
Placebo Montelukast Beclomethasone Total
N Z 359 N Z 574 N Z 181 N Z 1114
Median age (range), yr 34.0 (15e79) 34.0 (15e78) 36.0 (15e74) 34.5 (15e79)
Median duration of asthma (range), yr 16 (0.5e65) 16 (0.5e67) 17 (0.5e63) 16 (0.5e67)
Female, % 51.8 56.8 63.0 56.2
Male, % 48.2 43.2 37.0 43.8
History of allergic rhinitis, % 79.1 74.0 57.5 73.0
Mean FEV1  SD, L 2.4  0.7 2.3  0.7 2.1  0.6 2.3  0.7
Mean FEV1 % predicted  SD, % 67.2  10.7 65.6  10.4 64.5  10.0 65.9  10.5
Mean FEV1 reversibility  SD, % 27.5  10.9 30.2  13.0 27.2  11.0 28.9  12.1
Mean AM PEF  SD, L/min 369  99 361  96 332  97 359  99
Mean PM PEF  SD, L/min 395  102 384  100 350  97 382  101
Mean Daytime Symptom Score  SD 2.4  0.81 2.4  0.8 2.3  0.9 2.4  0.8
Mean Rescue b-agonist use  SD, puffs/day 5.3  3.5 5.3  3.3 5.4  4.2 5.3  3.4
Mean Nocturnal awakenings  SD, nights/wk 4.2  2.5 4.2  2.5 4.6  2.4 4.3  2.5
AQLQ (pooled domains) 3.4  1.1 3.5  1.1 3.2  1.1 3.4  1.1
Peripheral blood eosinophils  SD, cells  109/L 0.33  0.27 0.34  0.31 0.37  0.36 0.34  0.30
AQLQ Z asthma quality-of-life questionnaire, FEV1 Z forced expiratory volume in 1 s, PEF Z peak expiratory flow.
Table 3 Six factors explaining variance in disease activity: Their loadings and explained variance.a
Efficacy outcome variable Factor
1 2 3 4 5 6
Daytime
asthma
control
Nighttime-
predominant
asthma control
Airway
obstruction
Asthma
exacerbations
Clinical
lability
Airway
obstruction
lability
AQLQdActivity domain 0.89 0.17 0.18 0.08 0.01 0.00
AQLQdEnvironment domain 0.85 0.12 0.14 0.07 0.01 0.01
AQLQdEmotions domain 0.81 0.24 0.10 0.09 0.02 0.09
AQLQdSymptom domain 0.79 0.40 0.13 0.12 0.00 0.13
DSSdSymptom component L0.50 0.45 0.04 0.03 0.32 0.45
DSSdActivity component L0.51 0.37 0.04 0.03 0.35 0.42
Nocturnal awakenings (nights/wk) 0.26 0.90 0.13 0.05 0.01 0.10
Nocturnal asthma score 0.30 0.89 0.15 0.07 0.02 0.14
Rescue b-agonist use (puffs/d) 0.27 0.72 0.14 0.08 0.11 0.31
Asthma-free days 0.19 L0.73 0.09 0.16 0.05 0.34
FEV1 (L) 0.09 0.08 0.90 0.09 0.07 0.02
AM PEF (L/min) 0.20 0.11 0.89 0.09 0.03 0.03
PM PEF (L/min) 0.20 0.04 0.87 0.09 0.00 0.17
FEV1 (% predicted) 0.03 0.17 0.69 0.08 0.06 0.24
Asthma attacks 0.07 0.03 0.04 0.94 0.01 0.01
Oral corticosteroid rescue 0.08 0.05 0.06 0.94 0.02 0.01
Asthma exacerbations 0.11 0.17 0.21 0.50 0.04 0.10
Daily variability of DSSdActivity
component
0.00 0.03 0.02 0.02 0.90 0.01
Daily variability of DSSdSymptom
component
0.04 0.06 0.03 0.00 0.90 0.01
PEF diurnal variability 0.07 0.02 0.10 0.02 0.02 0.87
Rescue b-agonist use diurnal
variability
0.02 0.29 0.37 0.03 0.13 0.43
Percent variance explained by factor 33 13 9 8 7 6
Cumulative explained variance 33 46 55 63 70 76
a Values in bold represent statistically significant (P < 0.05) factor loadings (based on varimax rotation) and identify which variables
are included in each factor. AQLQ Z asthma quality-of-life questionnaire, DSS Z daytime symptoms score, FEV1 Z forced expiratory
volume in 1 s, PEF Z peak expiratory flow.
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Figure 1 Scree plot of principal component analysis. Prin-
cipal component analysis was performed on combined dataset
(n Z 1114) as described in Methods. Numbered factors on x-
axis correspond to factors in Table 3. Six factors had eigen-
values 1.0 (Table 4).
Lung function lability predicts asthma severity 505associated with specific levels of disease activity. We found
that altering cutoffs for average DSS and AQLQ-activity
domain had minimal effects on the results of the DA (Table
S1), supporting both our choice of cutoffs and the robust-
ness of the findings. In addition, when we restricted our
analysis to males or females, or in asthmatics <30 years or
30 years, there were no salient differences in the factor
structures or results of the discriminant analyses (data not
shown).Principal component and discriminant analyses in
an independent clinical trial
Because we defined high and low disease activity based in
part on data from the same studies in which we performed
the factor and discriminant analyses, it was important to
confirm these results using an independent trial. We
repeated these analyses using data from a trial in which
subjects were randomized to montelukast, inhaled beclo-
methasone, both montelukast and inhaled beclomethasone
or placebo following withdrawal of inhaled beclomethasoneTable 4 Results of discriminant analysis.
Factor Description Standardized
canonical
Coefficients
1 Daytime asthma
control
0.56
2 Nighttime-
predominant
asthma control
0.90
3 Airway obstruction 0.54
4 Exacerbations 0.18
5 Clinical lability 0.14
6 Airway obstruction
lability
0.75
Canonical correlation 0.69
Correct classification
of disease activity (%)
98.3%administered during the run-in period.8 The factor struc-
ture was similar to what was obtained for the combined
data set, except daytime symptoms mapped to Factor 4,
“clinical lability,” in addition to Factor 1 (Table S2). Results
of the discriminant analysis were similar to that of the
combined data set, in that airway lability had the second
highest standardized canonical coefficient, 0.83, compared
to nighttime-predominant asthma control, which had the
greatest (0.85); Table S3.Discussion
This analysis sought to determine the relations between
different variables that have been used to evaluate
different manifestations of clinical asthma. We used this
information to identify which grouping of outcome vari-
ables best distinguished between levels of disease activity.
The results were unanticipated, and revealed that the
factor comprising both diurnal variability in PEF and
diurnal variability in daytime and nighttime use of rescue
b-agonists was more discriminating in differentiating
high and low levels of disease activity than traditional
outcome measures, such as daytime symptoms and airway
obstruction.
Because the current analysis included outcome variables
not included in earlier factor analyses, including several
that have not previously been defined, our results differed
from those described in earlier studies. Nevertheless, the
results of the current PCA share some common features
with previous studies, including identifying airway
obstruction as a distinct factor12e15 and distinguishing
daytime- and nighttime-predominant attributes of
asthma.14 The finding that asthma-free days loaded onto
nighttime-predominant asthma control is consistent with
the close relationship between nocturnal manifestations of
asthma and overall control of asthma symptoms.16
The finding of separate factor structures for components
of the AQLQ, physiological variables, and nocturnal symp-
toms were similar to results reported by Juniper and
colleagues,14 and our finding of asthma exacerbations as
a distinct factor was also reported in a study by Schatz and
colleagues.17 In the present study, unlike one earlier
study,14 AQLQ domains did not load onto a distinct factor,
but instead were grouped with DSS. This is, perhaps, not
surprising, as many of the questions in the AQLQ inherently
reflect daytime symptoms (e.g., activity level, household
chores, etc.). Similarly, although the earlier study by
Juniper and colleagues14 did not include DSS per se, it did
include individual daytime symptoms, such as daytime
shortness of breath, daytime chest tightness, and activity
limitation. Despite not loading significantly onto the same
factor as the individual AQLQ domains in their study, these
variables demonstrated trends toward doing so.14
There is no “gold standard” in categorizing asthma
severity or disease activity. Some symptoms may be more
troubling to some asthmatics, but not others, which is likely
due, in part, to differences in patients’ perceptions of their
symptoms. In addition, different “endotypes” of asthma
have been described,18,19 which reflects the heterogeneity
of clinical manifestations of asthma, and likely disease
pathogenesis. These explanations may underlie the finding
506 S. Greenberg et al.that the correlation between different outcome measures
is generally low.1 Low correlation among outcome variables
implies that these variables measure different constructs of
disease activity. Indeed, we found that daily variability of
the DSS (both symptoms and activity) loaded onto a factor
separate from the factor including diurnal variability of PEF
and of rescue b-agonist use, perhaps reflecting manifesta-
tions of asthma that are distinct from the more traditional
variables.
We modeled our approach to define different levels of
disease activity based on the GINA3 and EPR32 guidelines,
recognizing their inherent limitations. Perhaps the biggest
challenge in this approach was how to define cutoffs for
each efficacy outcome variable. The goal was to set real-
istic cutoffs without making them so stringent that, for
example, all patients fall into the high level of disease
activity by default. Since we used a dichotomous high/low
classification, there is an inherent tendency for misclassi-
fication that increases with the number of variables.
Although the cutoffs that we chose to define high and low
levels of disease activity were based on empirical data and
existing guidelines, the sensitivity analysis, in which we
altered some of the cutoffs, did not change the funda-
mental conclusions of the study, suggesting that the
specific cutoffs we chose were not critical. In addition,
because each of the efficacy outcome variables that we
chose to define disease activity reflected different aspects
of clinical asthma, we propose that this approach exhibits
inherent content validity.
The utility of monitoring PEF diurnal variability in
asthma is controversial.
There is evidence that, in children, PEF variability
correlates with bronchial hyperresponsiveness and bron-
chodilator response, as well as with FEV1 and percentage of
symptom-free days.9,20 PEF variability, as expressed by
percentage difference in AM and PM PEF values, correlates
with measures of adverse sleep quality in asthmatics.21
Reduction of PEF diurnal variability has been observed
following treatment with leukotriene receptor antago-
nists22,23 suplatast toxylate24 and a monoclonal antibody
against tumor necrosis factor-a.25 On the other hand, PEF
relies on patient report, and is highly effort-dependent.
There is wide variability in reference values for PEF, and
there is no evidence that it is superior to other existing
outcome measures more commonly used in clinical trials.
As such, the EPR3 generally recommends PEF be used for
self-monitoring, alone or in combination with symptom
monitoring, in the context of a written asthma action plan
to determine the need for intervention.2 Thus, its utility as
an outcome measure in clinical trials should be considered
against these limitations. It should also be emphasized that
although the results of DA indicated a high correlation with
a factor comprising diurnal variability in both PEF and
rescue b-agonist use, it is possible that neither variable
alone that comprise this factor provides sufficient
discriminating power to maximally distinguish between
patients with high and low disease activity.
The main limitation of this analysis is that it was derived
from data from only two randomized controlled trials. There
were relatively strict inclusion and exclusion criteria,
appropriate for Phase-III registration trials. We chose these
trials because the similar designs, inclusion criteria, andconcurrent conduct allowed us to combine the datasets of
generally similar populations to increase sample size. In
addition,we limited our data tomontelukast studies because
of access to the raw datasets. Therefore, our results may not
apply to the general asthma population. Although the main
findings of the study were replicated in a third confirmatory
trial, further validationusingadditional datasets is needed to
verify the applicability to other medications, broader pop-
ulations, and other clinical settings.
In summary, we applied multivariate techniques to
analyze clinical trial data of patients treated with mon-
telukast, beclomethasone, or placebo to identify variables
that best discriminated asthmatics with different levels of
disease activity. We found that outcome variables such as
the combined measure of diurnal variation of both PEF and
b-agonist rescue use better distinguished levels of asthma
disease activity than many traditional outcome measures.
Use of these non-traditional variables in future clinical
trials may help better identify response to asthma therapy.
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